167 related articles for article (PubMed ID: 33159013)
1. The therapeutic value of XL388 in human glioma cells.
Zhong S; Xue J; Cao JJ; Sun B; Sun QF; Bian LG; Hu LY; Pan SJ
Aging (Albany NY); 2020 Nov; 12(22):22550-22563. PubMed ID: 33159013
[TBL] [Abstract][Full Text] [Related]
2. The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models.
Zhu YR; Zhou XZ; Zhu LQ; Yao C; Fang JF; Zhou F; Deng XW; Zhang YQ
Oncotarget; 2016 Aug; 7(31):49527-49538. PubMed ID: 27385099
[TBL] [Abstract][Full Text] [Related]
3. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
5. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
6. AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin.
Cheng Y; Zhao G; Zhang S; Nigim F; Zhou G; Yu Z; Song Y; Chen Y; Li Y
PLoS One; 2016; 11(12):e0167094. PubMed ID: 27907160
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.
Wen N; Guo B; Zheng H; Xu L; Liang H; Wang Q; Wang D; Chen X; Zhang S; Li Y; Zhang L
Int J Oncol; 2019 Oct; 55(4):879-895. PubMed ID: 31485609
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway.
Zhang C; Yuan XR; Li HY; Zhao ZJ; Liao YW; Wang XY; Su J; Sang SS; Liu Q
Cell Physiol Biochem; 2015; 35(2):419-32. PubMed ID: 25613036
[TBL] [Abstract][Full Text] [Related]
9. Oleuropein inhibits the proliferation and invasion of glioma cells via suppression of the AKT signaling pathway.
Liu M; Wang J; Huang B; Chen A; Li X
Oncol Rep; 2016 Oct; 36(4):2009-16. PubMed ID: 27498673
[TBL] [Abstract][Full Text] [Related]
10. Antiglioma effects of cytarabine on leptomeningeal metastasis of high-grade glioma by targeting the PI3K/Akt/mTOR pathway.
Zhao KH; Zhang C; Bai Y; Li Y; Kang X; Chen JX; Yao K; Jiang T; Zhong XS; Li WB
Drug Des Devel Ther; 2017; 11():1905-1915. PubMed ID: 28721010
[TBL] [Abstract][Full Text] [Related]
11. GDC-0084 inhibits cutaneous squamous cell carcinoma cell growth.
Ding LT; Zhao P; Yang ML; Lv GZ; Zhao TL
Biochem Biophys Res Commun; 2018 Sep; 503(3):1941-1948. PubMed ID: 30072096
[TBL] [Abstract][Full Text] [Related]
12. Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models.
Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Gjerde CH; Enger PØ; Goplen D
BMC Cancer; 2016 Aug; 16():657. PubMed ID: 27542970
[TBL] [Abstract][Full Text] [Related]
13. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
14. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
15. SF2523 inhibits human chondrosarcoma cell growth in vitro and in vivo.
Zhu JX; Xiao JR
Biochem Biophys Res Commun; 2019 Apr; 511(3):559-565. PubMed ID: 30824188
[TBL] [Abstract][Full Text] [Related]
16. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
17. GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo.
Zhou X; Shen F; Ma P; Hui H; Pei S; Chen M; Wang Z; Zhou W; Jin B
Mol Med Rep; 2015 Oct; 12(4):5641-6. PubMed ID: 26238593
[TBL] [Abstract][Full Text] [Related]
18. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
19. Isogambogenic Acid Inhibits the Growth of Glioma Through Activation of the AMPK-mTOR Pathway.
Zhao W; Peng F; Shu M; Liu H; Hou X; Wang X; Ye J; Zhao B; Wang K; Zhong C; Xue L; Gao M; Liu Y; Zhao S
Cell Physiol Biochem; 2017; 44(4):1381-1395. PubMed ID: 29186708
[TBL] [Abstract][Full Text] [Related]
20. Nitidine Chloride Is a Potential Alternative Therapy for Glioma Through Inducing Endoplasmic Reticulum Stress and Alleviating Epithelial-Mesenchymal Transition.
Chen Z; Zhang J; Xue H; Qian M; Guo X; Gao X; Xu J; Qi Y; Sun X; Li G
Integr Cancer Ther; 2020; 19():1534735419900927. PubMed ID: 32129091
[No Abstract] [Full Text] [Related]
[Next] [New Search]
